ArticleThe Korean journal of helicobacter and upper gastrointestinal research2025
Therapeutic Potential of Melatonin in Functional Dyspepsia.
Article in The Korean journal of helicobacter and upper gastrointestinal research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melatonin has demonstrated potential therapeutic benefits across a range of functional gastrointestinal disorders, including irritable bowel syndrome and heartburn, due to its effects on motility regulation, visceral sensitivity, and gut-brain signaling. To assess its efficacy specifically in functional dyspepsia (FD), we conducted a meta-analysis of three randomized controlled trials (RCTs) involving a total of 148 patients (74 in each of the melatonin and placebo groups). The primary outcome was symptom improvement following melatonin supplementation. The fixed-effect model revealed a statistically significant benefit (odds ratio [OR], 4.96; 95% confidence interval [CI], 2.19-11.27; p<0.001), whereas the random-effects model showed a non-significant trend toward improvement (OR, 4.59; 95% CI, 0.82-25.80). These findings indicate that melatonin may be a promising adjunctive treatment for FD. However, the small number of RCTs and the age of the included studies limit definitive conclusions; large‑scale, recent trials are needed to define the optimal target population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.